|

IgPro20 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Also known as: HIZENTRA, Immune Globulin Subcutaneous (Human) 20% Liquid

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Memorial Sloan Kettering Cancer Center1
  • CSL Behring1

Indications

  • Cancer2
  • Secondary Immune Deficiency1
  • Hypogammaglobulinemia, Acquired1
  • Hypogammaglobulinemia1
  • Multiple Myeloma1

Orange, California1 trial

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine

Phase 3

Basking Ridge, New Jersey1 trial

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.